More than 1% of the US adult population is affected by schizophrenia, with symptoms falling into three categories: positive (hallucinations and delusions), negative (flat affect, difficulty in social interactions) and cognitive (complications with attention and memory). The disease is currently treated with antipsychotics, which can lead to numerous serious side effects.
We are developing an enzyme replacement therapy, CM-182, that may be helpful in the treatment of schizophrenia. Animal model studies of CM-182 have shown effectiveness in treating the positive symptoms of schizophrenia without sedation.